Ultragenyx Pharmaceutical Inc. buy JPMorgan Chase & Co.
Start price
27.02.24
/
50%
€49.60
Target price
27.02.25
€81.12
Performance (%)
-19.76%
Price
03.05.24
€39.80
Summary
This prediction is currently active. The prediction for Ultragenyx Pharmaceutical Inc. disappoints with a performance of -19.76%. This prediction currently runs until 27.02.25. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Ultragenyx Pharmaceutical Inc. | -3.865% | -3.865% |
iShares Core DAX® | -0.922% | -1.993% |
iShares Nasdaq 100 | 0.371% | -0.868% |
iShares Nikkei 225® | 2.224% | -5.187% |
iShares S&P 500 | -0.026% | -0.918% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at JPMorgan Chase & Co. from $84.00 to $88.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat